101 – 110 of 533
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Diagnostic and prognostic factors in patients with prostate cancer : a systematic review
(
- Contribution to journal › Scientific review
-
Mark
Designing and Implementing a Population-based Organised Prostate Cancer Testing Programme
(
- Contribution to journal › Article
-
Mark
Learning curve for robot-assisted laparoscopic radical prostatectomy in a large prospective multicentre study
(
- Contribution to journal › Article
-
Mark
Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer
(
- Contribution to journal › Article
-
Mark
Bladder cancer recurrence in papillary urothelial neoplasm of low malignant potential (PUNLMP) compared to G1 WHO 1999 : a population-based study
(
- Contribution to journal › Article
-
Mark
Complete metabolic response with [18F]fluorodeoxyglucose-positron emission tomography/computed tomography predicts survival following induction chemotherapy and radical cystectomy in clinically lymph node positive bladder cancer
(
- Contribution to journal › Article
-
Mark
Analytical performance of aPROMISE : automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting
(
- Contribution to journal › Article
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter
-
Mark
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
(
- Contribution to journal › Article